Trial Profile
QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Inbakicept (Primary) ; Inbakicept (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 05 Oct 2022 Status changed from active, no longer recruiting to completed.
- 25 Feb 2022 Status changed to active, no longer recruiting.
- 01 Feb 2021 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.